Medical specialists from United Kingdom tagged as investigators in clinical trials studying Polycythemia Vera

Total 10 results

Adam Mead
Seen in:
- Oxford, Oxford University Hospitals NHS Foundation Trust, Department of Haematology, Cancer and Haematology Centre, Churchill Hospital
Trials:
- NCT04603495 (Principal Investigator)
Conditions:
Andrew Duncombe, MD
Seen in:
- England, Southampton, University Hospitals Southampton NHS Foundation Trust
Trials:
- NCT01831635 (Principal Investigator)
Conditions:
Andrew Innes
Seen in:
- London, Imperial College Healthcare NHS Trust, Hammersmith Hospital
Trials:
- NCT04603495 (Principal Investigator)
Conditions:
Anna Godfrey
Seen in:
- Cambridge, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust
Trials:
- NCT04603495 (Principal Investigator)
Conditions:
Ciro Rinaldi, MD
Seen in:
- Boston, Pilgrim Hospital
Trials:
- NCT04603495 (Principal Investigator)
Conditions:
Ioannis Koutsavlis, MD
Seen in:
- Scotland, Edinburgh, Western General Hospital
Trials:
- NCT04603495 (Principal Investigator)
Conditions:
Jonathan Lambert
Seen in:
- London, University College London Hospitals
Trials:
- NCT04603495 (Principal Investigator)
Conditions:
Lesley A Anderson, PhD
Seen in:
- Northern Ireland, Belfast, Queen's University Belfast
Trials:
- NCT01831635 (Principal Investigator)
Conditions:
Mary F Mcmullin, MD
Seen in:
- Northern Ireland, Belfast, Belfast Health and Social Care Trust
Trials:
- NCT01831635 (Principal Investigator)
Conditions:
Steven Knapper, MD
Seen in:
- Wales, Cardiff, University Hospital of Wales
Trials:
- NCT04603495 (Principal Investigator)
- NCT04910685 (Principal Investigator)
Conditions:

Clinical Trials on Polycythemia Vera

PharmaEssentia Japan K.K.

Recruiting

Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients

Polycythemia Vera (PV)

Japan
Novartis Pharmaceuticals

Completed

Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea.

Polycythemia Vera (PV)

United States
PharmaEssentia Japan K.K.

Recruiting

A Study to Evaluate P1101 in Japanese PV Patients

Polycythemia Vera (PV)

Japan
PharmaEssentia Japan K.K.

Completed

Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply

Polycythemia Vera (PV)

Japan
Ionis Pharmaceuticals, Inc.

Recruiting

A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera

Phlebotomy Dependent Polycythemia Vera

United States, Canada, Hungary, United Kingdom, Australia, Poland
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company; Incyte Corporation

Recruiting

A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis

Myelofibrosis Due to and Following Polycythemia Vera

United States
Northwestern University
National Cancer Institute (NCI); Celgene; The Leukemia and Lymphoma Society

Withdrawn

Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase

United States
Novartis Pharmaceuticals

Terminated

A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary Myelofibrosis

Primary Myelofibrosis | Post-Polycythemia Vera | Post-Essential Thrombocytopenia

United States
Celgene

Recruiting

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions (INDEPENDENCE)

Primary Myelofibrosis | Myeloproliferative Disorders | Anemia | Myelofibrosis | Post-Polycythemia Vera Myelofibrosis

France, Belgium, Spain, Australia, Canada, United States, Korea, Republic of, Romania, Japan, Israel, Italy, Austria, China, Czechia, Germany, Greece, Ireland, Poland, United Kingdom, Hong Kong, Hungary, Lebanon, Argentina, Chile, Colombia and more
Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Active, not recruiting

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM2)

Primary Myelofibrosis | Myelofibrosis | Post-Polycythemia Vera

Australia, Austria, Belgium, China, Czechia, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Ireland, United Kingdom

Medical specialists from United Kingdom tagged as investigators in clinical trials studying Polycythemia Vera

Clinical Trials on Polycythemia Vera

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Azerbaijan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations